Global Overactive Bladder Treatment Market Growth (Status and Outlook) 2023-2029

Global Overactive Bladder Treatment Market Growth (Status and Outlook) 2023-2029

Product Code:457644

Published Date: Feb 08,2023

Pages: 87

Region: Global

Category: Medical Devices & Consumables

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

SELECT A FORMAT

ADD TO BASKET

BUY NOW

Provide comprehensive and accurate analysis and reports according to your exact requirements

Provide comprehensive and accurate analysis and reports according to your exact requirements

CONTACT US

Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device.

LPI (LP Information)' newest research report, the “Overactive Bladder Treatment Industry Forecast” looks at past sales and reviews total world Overactive Bladder Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Overactive Bladder Treatment sales for 2023 through 2029. With Overactive Bladder Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Overactive Bladder Treatment industry.

This Insight Report provides a comprehensive analysis of the global Overactive Bladder Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Overactive Bladder Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Overactive Bladder Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Overactive Bladder Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Overactive Bladder Treatment.

The global Overactive Bladder Treatment market size is projected to grow from US$ 4989.1 million in 2022 to US$ 6182.8 million in 2029; it is expected to grow at a CAGR of 3.1% from 2023 to 2029.

Global Overactive Bladder Treatment key players include Allergan, Astellas Pharma, Pfizer, Johnson & Johnson, Medtronic, etc. Global top five manufacturers hold a share about 90%. United States is the largest market, with a share about 60%, followed by Europe, with a share about 15 percent. In terms of product, Drugs is the largest segment, with a share about 95%. And in terms of application, the largest application is Idiopathic Overactive Bladder, followed by Neurogenic Overactive Bladder.

This report presents a comprehensive overview, market shares, and growth opportunities of Overactive Bladder Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:
Segmentation by type
    Drugs
    Device

Segmentation by application
    Idiopathic Overactive Bladder
    Neurogenic Overactive Bladder

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
    Allergan
    Astellas Pharma
    Pfizer
    Johnson & Johnson
    Medtronic
    KYORIN Pharmaceutical